Substitution of 1,4-dihydro-4-oxoquinoline-2-carboxylic acid by acetyl, benzoyl, and phenylsulfonyl substituents was found to enhance activity in the rat passive cutaneous anaphylaxis assay. A further increase in activity, to equipotency with DSCG, was achieved by incorporation of the 8-benzoyl moiety into a tetracyclic structure to give 1,4-dihydro-4,11(1H,11H)-dioxoindeno[1,2-h]quinoline-2-carboxylic acid (20). In contrast, the reverse isomer 19 was found to have little activity.
Twenty-four m-and p-(phenoxyalkoxy)beiizamidines bearing a terminal sulfonvl fluoride moiety were synthesized and evaluated as irreversible inhibitors of trypsin; all were excellent reversible inhibitors with K, -0.7-3.0 µ . Eight (2, 3, 5, 6,(19)(20)(21) 24) were excellent active-site-directed irreversible inhibitors when assayed at a K¡ concentration giving 88-100% inactivation. Four (13,(15)(16)(17) showed no irreversible inhibition when assayed at an 8K¡ concentration. The remaining twelve were poor irreversible inhibitors at a >K¡ concentration. One of the excellent irreversible inhibitors of trypsin was p-[p-(p-fluorosulfonyibenzamido)phenoxypropoxy]benzamidine (2), which showed no irreversible inhibition of a related "tryptic" enzyme, namely, thrombin; this specificity is presumably due to the probability that the S02F moiety of 2 forms a covalent bond "outside" the active site where structural differences between trypsin and thrombin are apt to be present. The possibility of design of inhibitors of opposite specificity, that is, inactivation of thrombin with no inactivation of trypsin, by appropriate modification of benzamidine and phenylgttanidine is discussed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.